Curing blindness through regenerative cell therapies. We replace what is lost.
StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness.
We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.
The most innovative startup in health and life sciences in Europe at BioFit, 2020
Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023
Latest news
26/9/2024
StemSight selected for BIO Europe Startup Spotlight finals
Europe's premier partnering event will be held in Stockholm on 4-6 November. StemSight has been selected as one of the 8 companies to pitch in the Startup Sportlight session in front of a panel of expert judges. Our CEO Laura Koivusalo will be on stage and available for partnering at the event.
29/4/2024
StemSight is presenting at Bio€quity 2024
On May 12 to May 15, our CEO Laura Koivusalo will be attending the Bio€quity biotech investor meeting in San Sebastian, Spain. Laura will give a presentation about StemSight and our latest achievements on May 14 at 11:00 as part of the Cell and Gene Therapy Track. Meetings with Laura can be requested through the event partnering system!
22/03/2024
StemSight moves to second phase of EIC Accelerator
As an innovative technology company focused on creating lasting benefits to the European health ecosystem, StemSight is a prime candidate for EU's EIC Accelerator funding. This highly competitive funding scheme requires two application phases, and a final interview. We are glad to announce that we have received very positive evaluation from the four independent evaluators on our first phase application and are eager to move to the next step!
7/6/2024
Laura Koivusalo on stage at HLTH Europe
The legendary HLTH event lands in Amsterdam on the 17th-20th of June! Our CEO Laura is speaking on the Startup Stage on the final day of the event in the EIT Health Catapult panel.
6/5/2024
StemSight wins Dragon's Den competition at Finnish Biotechs & Investors meeting
Tesi, Innovestor and HealthCap co-organized the first Finnish Biotechs and Investors meeting, where StemSight participated in the Dragon's Den -type pitching competition. StemSight was selected as the winner from the pitching companies!
19/03/2024
Laura Koivusalo speaks at Advanced Therapies in London
Our CEO Laura attends the Advanced Therapies event in London on March 19-20. Laura joins other prominent Cell and Gene Therapy leaders in an expert panel on Autologous vs. Allogeneic approaches in cell therapy.
Investor presentation
We are in discussions with international biotech and life science investors and corporates to get our life-changing products to first patients.
Curious?
Want to know more?
Interested to join our next investment round?
Want to hear about our latest developments?
Just thought of someone we absolutely need to meet?
Send us a message!
Supported by:
Co-funded by:
